FDA Revokes EUAs for Four Monoclonal Antibody Products
December 13, 2024 -- At the request of the individual product sponsors, FDA has revoked the Emergency Use Authorizations (EUAs) for four respective monoclonal antibody (mAb) products that had been authorized for emergency use as part of the United States government’s response to the COVID-19 public health emergency.
As of today, the EUAs for bebtelovimab, Evusheld (tixagevimab co-packaged with cilgavimab), sotrovimab, and REGEN-COV (casirivimab and imdevimab) have been revoked.
The four mAb products have not been authorized for administration to patients for more than a year due to the high frequency of circulating SARS-CoV-2 variants that are not susceptible to each particular mAb product. Previously, FDA, at the appropriate time, based on a limitation in each EUA, announced that the respective mAb product was no longer authorized for emergency use. The limitation allowed each EUA to remain in place, and in turn, permitted health care facilities and providers to retain inventory of the particular mAb product in case the susceptibility of future SARS-CoV-2 variants changed. However, the high frequency of circulating SARS-CoV-2 variants that are non-susceptible to these particular mAb products has persisted. In addition, the shelf life for nearly all lots of these products has expired.
The sponsor for each of these revoked EUAs will provide health care facilities and providers with instructions for return and disposal of each respective product.
Source: FDA
Posted December 2024
Read this next
How Wildfires Might Increase Risk Of Flu, COVID-19
WEDNESDAY, June 18, 2025 — Wildfires might inadvertently increase the risk of flu and COVID-19 outbreaks, a new study argues. Sky-choking wildfire smoke tends to drive...
CDC Vaccine Expert Resigns After RFK Jr. Cuts Advisers
WEDNESDAY, June 18, 2025 — A senior scientist at the U.S. Centers for Disease Control and Prevention (CDC) has resigned, warning that changes in leadership may weaken the...
New COVID Variant, NB.1.8.1, May Now Make Up 1 in 3 U.S. Cases
MONDAY, June 16, 2025 — A new COVID-19 variant that led to a spike in hospital cases across parts of Asia may now account for more than one-third of all COVID cases in the...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.